Regression of Endometrial Implants by Resveratrol in an Experimentally Induced Endometriosis Model in Rats

Ahmet Mete ErgenoÄŸlu, Ergenoğlu AM, Ahmet Mete Ergenoğlu, Ahmet Özgür Yeniel, Ahmet Ãzgür Yeniel, Oytun ErbaÅŸ, Oytun Erbaş, Hüseyin Aktuğ, Hà ⁄ seyin AktuÄŸ, Nuri Yıldırım, Nuri Yildirim, Ulukuş M, Murat UlukuÅŸ, Murat Ulukuş, Dilek Taşkıran, Dilek Taskiran
Reproductive sciences (Thousand Oaks, Calif.) · 2013 · vol. 20(10) , pp. 1230–1236 · doi:10.1177/1933719113483014 · PMID:23536571 · W2042153379
article OA: closed CC0 ⤵ 47 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-06-13 ⓘ

Resveratrol treatment significantly reduced endometriotic implant size, decreased inflammatory markers, and suppressed VEGF expression in a rat model of endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-06 · read from full text ⓘ

This study evaluated whether resveratrol could regress surgically induced endometriotic implants in rats by administering 10 mg/kg/day for a treatment period and assessing inflammatory markers plus histopathology at the end. Rats were randomized to saline controls (n=6) or resveratrol (n=6), and the authors measured changes in implant size and angiogenic/inflammatory mediators including VEGF and MCP-1 in both peritoneal fluid and plasma, along with VEGF expression in endometriotic tissue. Resveratrol significantly reduced implant size, decreased VEGF levels and MCP-1 levels, and suppressed VEGF expression in the implants, accompanied by considerable histological changes in treated foci. The paper’s main caveat is that only one dose and a small sample size were tested, with the authors calling for future studies using different doses to broaden the findings. This paper is centrally about endometriosis — resveratrol-mediated regression of experimentally induced endometrial implants in a rat endometriosis model via antiangiogenic and anti-inflammatory effects.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

ObjectiveTo evaluate the effect of resveratrol on an experimentally induced endometriosis rat model.Study designAfter endometriotic implants were surgically formed, rats were randomly divided into 2 groups as control group (saline treated, n = 6) and resveratrol group (10 mg/kg/d, n = 6). The inflammatory markers and histopathological changes were assessed at the end of the treatment period. Results Our results showed (1) significant reduction in the implant size (P < .0005); (2) significantly decreased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid and plasma (P < .005); and monocyte chemotactic protein 1 (MCP-1) in the peritoneal fluid (P < .05), (3) highly significant suppression of VEGF expression in the endometriotic tissue (P < .0005); and (4) considerable histological changes in the endometriotic foci following resveratrol treatment.ConclusionResveratrol appears to be effective on the development of endometriosis through its antiangiogenic and anti-inflammatory properties. Future studies with different doses of resveratrol might provide more comprehensive results regarding the treatment of endometriosis.
Full text 7,028 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Abstract

Objective To evaluate the effect of resveratrol on an experimentally induced endometriosis rat model. Study design After endometriotic implants were surgically formed, rats were randomly divided into 2 groups as control group (saline treated, n = 6) and resveratrol group (10 mg/kg/d, n = 6). The inflammatory markers and histopathological changes were assessed at the end of the treatment period.

Results

Our results showed (1) significant reduction in the implant size (P < .0005); (2) significantly decreased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid and plasma (P < .005); and monocyte chemotactic protein 1 (MCP-1) in the peritoneal fluid (P < .05), (3) highly significant suppression of VEGF expression in the endometriotic tissue (P < .0005); and (4) considerable histological changes in the endometriotic foci following resveratrol treatment.

Conclusion

Resveratrol appears to be effective on the development of endometriosis through its antiangiogenic and anti-inflammatory properties. Future studies with different doses of resveratrol might provide more comprehensive results regarding the treatment of endometriosis. Similar content being viewed by others

References

Oral E, Arici A. Pathogenesis of endometriosis. Obstet Gynecol Clin North Am. 1997;24(2):219–233. Goldman MB, Cramer DW. The epidemiology of endometriosis. Prog Clin Biol Res. 1990;323:15–31. Vinatier D, Dufour P. Is endometriosis an immunological disease? Contracept Fertil Sex. 1997;25(3):179–191. Iborra A, Palacio JR, Ulcova-Gallova Z, Martínez P. Autoimmune response in women with endometriosis. Am J Reprod Immunol. 2000;44(4):236–241. Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril. 2001;76(2):223–231. Van Langendonckt A, Casanas-Roux F, Donnez J. Oxidative stress and peritoneal endometriosis. Fertil Steril. 2002;77(5): 861–870. Sasson IE, Taylor HS. Stem cells and the pathogenesis of endometriosis. Ann NY Acad Sci. 2008;1127:106–115. Taylor HS, Osteen KG, Bruner-Tran KL, et al. Novel therapies targeting endometriosis. Reprod Sci. 2011;18(9):814–823. Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem. 2012;113(3):752–759. Markus MA, Morris BJ. Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging. 2008; 3(2):331–339. Zhong M, Cheng GF, Wang WJ, Guo Y, Zhu XY, Zhang JT. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine. 1999;6(2): 79–84. Miura T, Muraoka S, Ikeda N, Watanabe M, Fujimoto Y. Antioxidative and prooxidative action of stilbene derivatives. Pharmacol Toxicol. 2000;86(5):203–208. Chen CJ, Yu W, Fu YC, Wang X, Li JL, Wang W. Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun. 2009;378(3):389–393. Kang OH, Jang HJ, Chae HS, et al. Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK. Pharmacol Res. 2009;59(5):330–337. Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther. 2009;11(6):R165. Vernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985;44(5):684–694. Güney M, Oral B, Karahan N, Mungan T. Regression of endometrial explants in a rat model of endometriosis treated with melatonin. Fertil Steril. 2008;89(4):934–942. Busquets S, Ametller E, Fuster G, et al. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett. 2007;245(1–2):144–148. Keenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril. 1999;72(1):135–141. Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab. 1995;80(6):1853–1858. Bruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K, Duleba AJ. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod. 2011;84(1):106–112. Kundu JK, Shin YK, Kim SH, Surh YJ. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking kappaB kinase activity. Carcinogenesis. 2006;27(7):1465–1474. Kumar A, Sharma SS. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun. 2010; 394(2):360–365. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update. 2000;6(1):45–55. Mahnke JL, Dawood MY, Huang JC. Vascular endothelial growth factor and interleukin 6 in peritoneal fluid of women with endometriosis. Fertil Steril. 2000;73(1):166–170. Kupker W, Schultze-Mosgau A, Diedrich K. Paracrine changes in the peritoneal environment of women with endometriosis. Hum Reprod Update. 2000;4(5):719–723. D’Antonio M, Martelli F, Peano S, Papoian R, Borrelli F. Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol. 2000;48(2):81–98. Iwabe T, Harada T, Tsudo T, et al. Tumor necrosis factor-alpha promotes proliferation of endometriotic stromal cells by inducing interleukin 8 gene and protein expression. J Clin Endocrinol Metab. 2000;85(2):824–829. Kang L, Heng W, Yuan A, Baolin L, Fang H. Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: relative to inhibition of inflammatory responses. Biochimie. 2010;92(7):789–796. Gazvani R, Templeton A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction. 2002;123(2):217–226. Arici A, Oral E, Attar E, Tazuke SI, Olive DL. Monocyte chemotactic protein-1 concentration in peritoneal fluid in patients with endometriosis and its modulation in human mesothelial cells. Fertil Steril. 1997;67(6):1065–1072. Ulukus M, Ulukus EC, Tavmergen Goker EN, Tavmergen E, Zheng W, Arici A. Expression of interleukin-8 and monocyte chemotactic protein 1 in women with endometriosis. Fertil Steril. 2009;91(3):687–693. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article ErgenoÄŸlu, A.M., Yeniel, A.Ã., ErbaÅŸ, O. et al. Regression of Endometrial Implants by Resveratrol in an Experimentally Induced Endometriosis Model in Rats. Reprod. Sci. 20, 1230–1236 (2013). https://doi.org/10.1177/1933719113483014 Published: Issue date: DOI: https://doi.org/10.1177/1933719113483014

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Disease Models, Animal Endometriosis Endometriosis Endometrium Stilbenes Animals Endometriosis Endometrium Endometrium Female Random Allocation Rats Rats, Sprague-Dawley Remission Induction Remission Induction Resveratrol Stilbenes Stilbenes

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (47)

Source provenance

europepmc
last seen: 2026-08-19T06:08:28.815611+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:05.543671+00:00
unpaywall
last seen: 2026-08-19T06:23:00.919175+00:00
License: CC0 · commercial use OK